Physician profile
Taylor Dillard
NPI 1205636461
$1,817.06
in general payments reported to CMS, 2019-2025
20 companies · $1,817 in 2025
The $1,817 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $492.70 | 2025 | |
| Sk Life Science, INC. | $191.75 | 2025 | Xcopri |
| Argenx US, INC. | $179.57 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $138.65 | 2025 | Rystiggo, Briviact |
| Eisai INC. | $113.42 | 2025 | |
| Amneal Pharmaceuticals LLC | $82.13 | 2025 | Crexont |
| Janssen Biotech, INC. | $81.79 | 2025 | |
| Jazz Pharmaceuticals INC. | $81.55 | 2025 | |
| Biogen, INC. | $73.94 | 2025 | Skyclarys, Leqembi, Vumerity |
| Alexion Pharmaceuticals, INC. | $71.96 | 2025 | Ultomiris |
| Tg Therapeutics, INC. | $71.72 | 2025 | |
| Tanabe Pharma America, INC. | $52.02 | 2025 | Radicava |
| Amgen INC. | $31.98 | 2025 | Uplizna |
| Lundbeck LLC | $30.81 | 2025 | Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $29.68 | 2025 | Hyqvia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.22 | 2025 | Kisunla, Amyvid |
| Pfizer INC. | $21.11 | 2025 | |
| Csl Behring | $16.86 | 2025 | Hizentra |
| Neurelis, INC. | $16.12 | 2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $16.08 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Dillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.